Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty

Authors

• Hala H. Swaiss, From the National Center for Diabetics, Endocrinology and Genetics (Swaiss, Khawaja, Farahid, Ajlouni), University of Jordan, Amman, and from Department of Community Medicine (Batieha), Jordan University for Science and Technology, Irbid, Jordan
• Nahla M. Khawaja, From the National Center for Diabetics, Endocrinology and Genetics (Swaiss, Khawaja, Farahid, Ajlouni), University of Jordan, Amman, and from Department of Community Medicine (Batieha), Jordan University for Science and Technology, Irbid, Jordan
• Oraib H. Farahid, From the National Center for Diabetics, Endocrinology and Genetics (Swaiss, Khawaja, Farahid, Ajlouni), University of Jordan, Amman, and from Department of Community Medicine (Batieha), Jordan University for Science and Technology, Irbid, Jordan
• Anwar M. Batieha, From the National Center for Diabetics, Endocrinology and Genetics (Swaiss, Khawaja, Farahid, Ajlouni), University of Jordan, Amman, and from Department of Community Medicine (Batieha), Jordan University for Science and Technology, Irbid, Jordan
• Kamel M. Ajlouni, From the National Center for Diabetics, Endocrinology and Genetics (Swaiss, Khawaja, Farahid, Ajlouni), University of Jordan, Amman, and from Department of Community Medicine (Batieha), Jordan University for Science and Technology, Irbid, Jordan

Abstract

Objectives: To study the effect of gonadotropin-releasing hormone analogue (GnRHa) on final adult height (FAH) among Jordanian children with central precocious puberty (CPP). Methods: It is a retrospective historical cohort study. We assessed the FAH and height gain in 43 children with CPP (39 females and 4 males) who received GnRHa and 13 children with CPP (11 females and 2 males) who did not receive GnRHa and achieved FAH between 2004 and 2014. Final adult height was compared to target height (TH) and mid- parental height (MPH) in both groups. Results: In GnRHa treated females, the FAH was 158.5±6.6 cm compared to 151.2±8.4 cm in the untreated females ( p =0.004). Height gain was 2.9±8.5 cm in the treated females compared to -3.8±7.7 cm in the untreated group ( p =0.022). In GnRHa treated females, FAH was found to be closer to TH ( p =0.01) and MPH ( p =0.01) in comparison to untreated females. Conclusion: Gonadotropin-releasing hormone analogue is effective in increasing FAH in Jordanian children with CPP, particularly those with advanced bone age.

Article Type

Research Article

First Page

1101

Last Page

1107

Recommended Citation

Swaiss, Hala H.; Khawaja, Nahla M.; Farahid, Oraib H.; Batieha, Anwar M.; and Ajlouni, Kamel M. (2017) "Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty," Saudi Medical Journal: Vol. 38: Iss. 11, Article 5.
DOI: https://doi.org/10.15537/smj.2017.11.21187